

07 Aprile 2026

IRST IRCCS  
"Dino Amadori"  
Meldola (FC)

SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA  
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricevero e Cura a Carattere Scientifico

ISTITUTO  
ROMAGNOLO  
PER LO STUDIO  
DEI TUMORI  
DINO AMADORI

With Patronage of



# LUNG CANCER: WHERE WE ARE?

Fourth Edition

SCIENTIFIC CHAIRS:

Angelo Delmonte  
Nicola Normanno  
Elisabetta Parisi  
Lucio Crinò

PROMOTED BY

IRST IRCCS "Dino Amadori"  
MELDOLA  
UFFICIO FORMAZIONE:  
ufficio.formazione@irst.emr.it

Provider n. 2773 e  
Segreteria Organizzativa



# SCIENTIFIC RATIONALE

Lung cancer is the first cause of death for tumors worldwide.

However several improvements have been obtained mainly due to the increased biologic knowledge.

In fact today with the term lung cancer we consider a group of several diseases, distinguished according to histology and molecular features.

These aspects are fundamental in order to define the most active therapeutic strategies. This landscape is rapidly evolving and every year new data are available.

So far it is particularly important to have the possibility to discuss the new data together with outstanding experts in order to improve the knowledge for a better cure for patients.

# SCIENTIFIC PROGRAM

**08.30 Registration**

**09.00 Greetings from Directors  
and from Scientific Chairs**

**Early stage and locally  
advanced non small-cell  
lung cancer**

**Chairs**

**E. Parisi Meldola (FC)  
S. Tamberi Ravenna  
A. Romeo Rimini**

**9.15 Screening update in Europe in  
lung cancer**  
**U. Pastorino Milano**

**9.30 Pre-operative staging for  
NSCLC**  
**V. Poletti Forli**

**09.45 Surgery after neoadjuvant  
chemo-immunotherapy: more  
difficulties and how to overtake  
them**  
**D. Argnani Ravenna**

**10.00 Neoadjuvant approaches in  
early stages, non oncogene  
addicted NSCLC: how to choose  
between pre and peri operative  
approach**  
**A. Ardizzoni Bologna**

**10.15 Adjuvant approaches in early  
stages: an evolving landscape**  
**F. Passiglia Orbassano**

**10.30 Stage IIIB unresectable,  
locally advanced NSCLC**  
**M. Tiseo Parma**

**10.45 Radiotherapy as an  
alternative to surgery in early  
stage NSCLC**  
**A. Filippi Milano**

**11.00 Discussion**

**11.15 Coffee Break**

**Oncogene addicted,  
advanced diseases (Session  
also accredited for Nurses  
and Biologists)**

**Chairs**

**P. Ulivi Meldola (FC)  
L. Crinò Meldola (FC)**

**11.30 Sex and gender in lung  
cancer: which role?**  
**R. Berardi Ancona**

**11.45 Liquid biopsy in lung cancer:  
where are we?**  
**U. Malapelle Napoli**

**12.00 EGFR mutants: different  
therapies for different tumors**  
**A. Passaro Milano**

**12.15 KRAS oncogene addicted  
tumors**  
**D. Cortinovis Monza**

**12.30 Rare oncogene addicted  
tumors (ALK, ROS1, BRAF, RET, MET,  
NTRK, HER2)**  
**K. Andrikou Meldola (FC)**

# SCIENTIFIC PROGRAM

**12.45 Antibody Conjugates in lung cancer**  
F. Fusco Roma

**13.00 Discussion**

**13.15 Light Lunch**

**Advanced non-oncogene driven diseases**

**Chairs**

C. Bennati Ravenna  
L. Ridolfi Meldola (FC)

**14.15 Artificial Intelligence in lung cancer**  
L. Mazzeo Milano

**14.30 Immunotherapy in NSCLC: how to use it**  
R. Chiari Pesaro

**14.45 Mechanism of Resistance to immunocheckpoint inhibitors**  
G. Lamberti Bologna

**15.00 New ways in immunotherapy**  
S. Pilotto Verona

**15.15 Phase 1 clinical trial: advantages and limits in NSCLC**  
M. Filetti Roma

**15.30 Discussion**

**Rare Thoracic Cancers (Session also accredited for Nurses and Biologists)**

**Chairs**

D. Tassinari Rimini  
A. Delmonte Meldola (FC)

**15.45 Tumors of the Thymus: future perspectives**  
T. M. De Pas Bergamo

**16.00 Small Cell Lung Cancer: state of the art for local and extended disease**  
A. Verlicchi Meldola (FC)

**16.15 Small Cell Lung Cancer: new therapeutic options**  
F. Bertolini Modena

**16.30 Pleural mesothelioma: a new landscape?**  
L. Calabrò Ferrara

**16.45 Discussion**

**17.00 Conclusions**

Con il contributo educativo non  
condizionante di

AstraZeneca 



Boehringer  
Ingelheim

 Bristol Myers Squibb®

 Daiichi-Sankyo

AstraZeneca 

Johnson & Johnson

**MERCK**

 **MSD**

*Pharma  
Mar* 

 *Pfizer*  
Oncology

**REGENERON**  
SCIENCE TO MEDICINE®

The Roche logo, which is the word "Roche" in a blue, sans-serif font inside a blue hexagonal border.

The Takeda logo, featuring the word "Takeda" in a red, serif font inside a red, stylized banner.

## ISCRIZIONE

L'iscrizione si effettua  
scaricando

**L'APP PROEVENTI**



**1. Scarica l'app PROEVENTI  
sul tuo smartphone**

**2. Crea il tuo account con le  
proprie credenziali o fai il  
login se già iscritto**

**3. Inserire il pin dell'evento:  
per Medico Chirurgo  
LUNG26**

**per Altre Discipline  
CANCER26**

**4. Ora sei sulla pagina  
dell'evento,  
clicca su ISCRIZIONE in alto  
a sinistra**

**5. Clicca su ISCRIVITI QUI**

## PROMOSSO DA

**IRST IRCCS MELDOLA "Dino Amadori"  
UFFICIO FORMAZIONE:  
ufficio.formazione@irst.emr.it**

## CREDITI ECM

**Evento n° 2773 - 473506**

**Obiettivo n. 3**

**N. 7 crediti ECM per:**

- Medici (Malattie dell'apparato respiratorio; Oncologia; Radioterapia; Chirurgia Generale; Anatomia Patologica; Medicina Nucleare; Radiodiagnostica)
- Farmacisti

**Evento n° 2773 - 473510**

**Obiettivo n. 3**

**N. 3 crediti ECM per:**

- Biologi
- Infermieri

## SEDE CONGRESSUALE

**Via Piero Maroncelli, 40,  
47014 Meldola (FC)**

## SEGRETERIA ORGANIZZATIVA E PROVIDER



**info@proeventi.it  
www.proeventi.it**